← All trials
NCT03985982
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 29, 2019
- Primary completion
- Mar 31, 2020
- Completion date
- Mar 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 353
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Croma-Pharma GmbHLead sponsor
- Yuvell (Austria)Overall official - principal investigator
- Tennessee Clinical Research CenterOverall official - principal investigator
- SKINTASTIC MedicalOverall official - principal investigator
- Skin Research Institute LLCOverall official - principal investigator
- University of PennsylvaniaOverall official - principal investigator
- Aesthetic Solutions P.A.Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.